Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Eribulin Mesylate

These are related to the Eribulin Mesylate news, in which you can learn about the latest trends in Eribulin Mesylate and related information industry, to help you better understand and expand Eribulin Mesylate market.
  • Drug Patent & Exclusivity Expiration Report - Week of Sep 08 2025

    Drug Patent & Exclusivity Expiration Report - Week of Sep 08 2025

    2025-09-08

    This week, there are 6 drugs in the patent and exclusivity list. They are: - GERON CORP's RYTELO, containing active ingredient IMETELSTAT SODIUM - MYLAN SPECIALTY LP's EPIPEN JR., containing active ingredient EPINEPHRINE - MYLAN SPECIALTY LP's EPIPEN, containing active ingredient EPINEPHRINE - BAUSCH AND LOMB INC's PROLENSA, containing active ingredient BROMFENAC SODIUM - EISAI INC's HALAVEN, containing active ingredient ERIBULIN MESYLATE - MERIDIAN MEDICAL TECHNOLOGIES LLC's SEIZALAM, containing active ingredient MIDAZOLAM HYDROCHLORIDE Read More